Details of the Drug Pharmacogenomic Perturbation Atlas

Vinorelbine Drug Info

Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID

5311497

ChEBI ID

CHEMBL480999

CAS Number

CAS 71486-22-1

TTD Drug ID

D01HTL

VARIDT Drug ID

DR01343

INTEDE Drug ID

DR1696

General Information of Drug (ID: DMVXFYE)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.32	0.00e+0	19/20 (95%)	SQLE;MSMO1;LSS;...
Dilated cardiomyopathy	2.17	0.00e+0	86/96 (89.58%)	ITGA5;TPM1;TPM4;...
Focal adhesion	2.16	0.00e+0	180/201 (89.55%)	ITGA5;LAMC2;TNC;...
Salmonella infection	2.05	0.00e+0	198/249 (79.52%)	S100A10;JUN;IRAK1;...
ECM-receptor interaction	2.01	2.18e-3	80/88 (90.91%)	ITGA5;LAMC2;TNC;...
Regulation of actin cytoskeleton	1.99	1.82e-3	185/218 (84.86%)	ITGA5;MSN;ACTN1;...
Bacterial invasion of epithelial cells	1.98	1.56e-3	59/77 (76.62%)	ITGA5;CAV1;ILK;...
ErbB signaling pathway	1.96	1.37e-3	79/85 (92.94%)	EREG;JUN;AREG;...
Proteoglycans in cancer	1.95	3.64e-3	172/205 (83.9%)	ITGA5;MSN;CAV1;...
Hypertrophic cardiomyopathy	1.86	4.37e-3	81/90 (90%)	ITGA5;TPM1;TPM4;...
Mineral absorption	1.85	6.95e-3	48/60 (80%)	MT1H;MT1HL1;MT1E;...
Renal cell carcinoma	1.85	7.28e-3	68/69 (98.55%)	JUN;CRK;PIK3CD;...
Terpenoid backbone biosynthesis	1.82	1.01e-2	18/22 (81.82%)	HMGCS1;FDPS;IDI1;...
GnRH secretion	1.82	9.36e-3	60/64 (93.75%)	GNA11;PRKCA;PIK3CD;...
Hippo signaling pathway	1.81	1.02e-2	120/186 (64.52%)	SERPINE1;AREG;PPP2CB;...
Pathogenic Escherichia coli infection	1.81	1.02e-2	152/197 (77.16%)	JUN;IRAK1;TUBA1A;...
Tight junction	1.80	9.64e-3	130/169 (76.92%)	MSN;JUN;ACTN1;...
AGE-RAGE signaling pathway in diabetic complications	1.79	1.21e-2	97/100 (97%)	F3;SERPINE1;JUN;...
MicroRNAs in cancer	1.78	1.15e-2	146/310 (47.1%)	ITGA5;TNC;TPM1;...
Vasopressin-regulated water reabsorption	1.78	1.15e-2	40/44 (90.91%)	ARHGDIA;GNAS;DYNC1I2;...
Long-term depression	1.74	1.87e-2	55/60 (91.67%)	PPP2CB;GNA11;PRKCA;...
Shigellosis	1.74	1.89e-2	180/246 (73.17%)	ITGA5;JUN;ACTN1;...
Colorectal cancer	1.72	1.90e-2	84/86 (97.67%)	EREG;JUN;AREG;...
MAPK signaling pathway	1.71	2.14e-2	272/294 (92.52%)	DUSP3;EREG;JUN;...
Arrhythmogenic right ventricular cardiomyopathy	1.71	2.14e-2	70/77 (90.91%)	ITGA5;ITGA3;DSC2;...
Yersinia infection	1.70	2.27e-2	120/137 (87.59%)	ITGA5;JUN;IRAK1;...
Chagas disease	1.68	2.51e-2	93/102 (91.18%)	SERPINE1;JUN;PPP2CB;...
Leukocyte transendothelial migration	1.68	2.46e-2	90/114 (78.95%)	MSN;ACTN1;ACTN4;...
Lysosome	1.68	2.41e-2	115/128 (89.84%)	NPC1;CTSB;LAMP1;...
Estrogen signaling pathway	1.66	2.64e-2	119/137 (86.86%)	KRT14;KRT17;JUN;...
Asthma	-1.63	2.50e-2	25/31 (80.65%)	HLA-DMB;HLA-DRB1;CCL11;...
Glutathione metabolism	-1.68	1.68e-2	43/57 (75.44%)	GSS;MGST3;GSR;...
Retinol metabolism	-1.74	9.18e-3	41/68 (60.29%)	CYP2C9;UGT2B15;ADH7;...
Autoimmune thyroid disease	-1.76	8.86e-3	46/53 (86.79%)	IFNA14;HLA-DMB;HLA-E;...
Propanoate metabolism	-1.77	7.84e-3	30/34 (88.24%)	ACSS3;ACAT1;SUCLG2;...
Porphyrin and chlorophyll metabolism	-1.78	8.15e-3	23/43 (53.49%)	ALAS2;BLVRB;UGT2B15;...
Type I diabetes mellitus	-1.79	7.38e-3	38/43 (88.37%)	IFNG;HLA-DQB1;GAD2;...
Nucleotide excision repair	-1.79	7.70e-3	40/47 (85.11%)	RFC4;GTF2H3;RFC3;...
ABC transporters	-1.79	7.65e-3	37/45 (82.22%)	ABCB7;ABCA5;ABCA6;...
Arachidonic acid metabolism	-1.81	7.17e-3	48/61 (78.69%)	PLA2G2A;PTGIS;CYP2J2;...
Citrate cycle (TCA cycle)	-1.88	2.21e-3	30/30 (100%)	PCK1;SDHA;SDHC;...
Oxidative phosphorylation	-1.90	1.87e-3	93/133 (69.92%)	ATP6V1A;COX6B1;ATP5PO;...
Histidine metabolism	-1.90	1.97e-3	16/22 (72.73%)	ALDH3A2;ALDH2;MAOB;...
Graft-versus-host disease	-1.90	2.08e-3	32/42 (76.19%)	HLA-DMB;HLA-E;PRF1;...
Antigen processing and presentation	-1.91	2.21e-3	60/78 (76.92%)	LGMN;CD8A;CREB1;...
Peroxisome	-1.92	2.36e-3	72/82 (87.8%)	ECI2;GSTK1;ACOT8;...
Fanconi anemia pathway	-1.93	2.53e-3	36/54 (66.67%)	RAD51C;FANCA;FANCE;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis	-1.93	2.73e-3	20/26 (76.92%)	GPLD1;PIGH;PIGN;...
Allograft rejection	-1.96	1.48e-3	32/38 (84.21%)	HLA-DMB;HLA-E;PRF1;...
Fatty acid degradation	-2.00	8.05e-4	40/43 (93.02%)	ADH1A;ACADVL;ACAA2;...
Steroid hormone biosynthesis	-2.05	0.00e+0	43/61 (70.49%)	UGT2B15;CYP2E1;CYP7B1;...
Pyruvate metabolism	-2.08	0.00e+0	41/47 (87.23%)	ADH1A;PCK1;ME3;...
Drug metabolism	-2.09	0.00e+0	78/151 (51.66%)	CYP2A6;MGST3;NME1;...
Tryptophan metabolism	-2.09	0.00e+0	35/42 (83.33%)	IDO1;AOC1;ACAT1;...
Mismatch repair	-2.15	0.00e+0	22/23 (95.65%)	EXO1;RFC4;RFC3;...
Metabolism of xenobiotics by cytochrome P450	-2.30	0.00e+0	49/77 (63.64%)	CYP2A6;MGST3;ADH1A;...
Folate biosynthesis	-2.34	0.00e+0	23/26 (88.46%)	PTS;PAH;MOCS1;...
Ribosome	-2.36	0.00e+0	113/158 (71.52%)	RPL5;RPS23;RPL7A;...
Glyoxylate and dicarboxylate metabolism	-2.37	0.00e+0	23/30 (76.67%)	ACAT1;MDH2;CS;...
DNA replication	-2.44	0.00e+0	34/36 (94.44%)	RFC4;PRIM2;MCM7;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
1HAEo-	CVCL_0128	Homo sapiens	10uM	24H

NL20	CVCL_0461	Homo sapiens	10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	4uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Normal (Fibroblast)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
HFL1	CVCL_4295	Homo sapiens	10uM	24H

IMR-90	CVCL_0347	Homo sapiens	10uM	24H

WI-38	CVCL_0579	Homo sapiens	10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H